Efficacy and safety of surufatinib (Sur) plus paclitaxel (Pac) as second line (2L) treatment for advanced gastric cancer (aGC): Final results from a phase 2 trial. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback